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ABSTRACT: Amphiphilic glycomimetics encompassing a rigid, undistortable nor-tropane 
skeleton based on 1,6-anhydro-L-idonojirimycin and a polyfluorinated antenna, when formulated 
as the corresponding inclusion complexes with β-cyclodextrin (βCD), have been shown to 
behave as pharmacological chaperones (PCs) that efficiently rescue lysosomal β-
glucocerebrosidase mutants associated to the neuronopathic variants of Gaucher disease (GD), 
including the highly refractory L444P/L444P and L444P/P415R single nucleotide polymorphs, 
in patient fibroblasts. The body of work here presented includes the design criteria for the PC 
prototype, the synthesis of a series of candidates, the characterization of the PC:βCD complexes, 
the determination of the selectivity profiles towards a panel of commercial and human lysosomal 
glycosidases, the evaluation of the chaperoning activity in type 1 (non-neuronopathic), 2 (acute 
neuronopathic) and 3 (adult neuronopathic) GD fibroblasts, the confirmation of the rescuing 
mechanism by immunolabeling and the analysis of the PC:GCase binding mode by docking 
experiments.  
Introduction 
Lysosomal acid β-glucosidase (β-glucocerebrosidase, GCase; EC 3.2.1.45) catalyzes the 
hydrolysis of the β-glycopyranosyl linkage in glucosylceramide (GlcCer) and 
glucosylsphingosine (GlcSph, psychosine) downstream in  glycosphingolipid metabolism, 
producing the free sugar and lipid components.1-3 Dysfunction of GCase results in progressive 
accumulation of undigested GlcCer and GlcSph in lysosomes of macrophage cells and visceral 
organs,4,5 which is the underlying pathological manifestation of Gaucher disease (GD), the 
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lysosomal storage disorder (LSD) with the highest prevalence (1 in 57,000 live births in the 
general population; 1 in 1,000 in Ashkenazi Jews).6,7 For operational purposes, GD is subdivided 
in three clinical types depending on the age of onset and the severity of the symptoms. Type 1 
GD (OMIM# 230800) is non-neuropathic and benefits from the availability of enzyme 
replacement therapy (ERT, i.e., supplementation with a recombinant GCase enzyme)8 and 
substrate reduction therapy (SRT, i.e., administration of inhibitors of substrate biosynthesis).9,10 
In contrast, type 2 and 3 GD (OMIM# 230900, and 231000, respectively), which accounts for 5-
10% of patients worldwide, course with neurological deterioration and remain orphan.11  
The origin of GCase dysfunction causing GD is diverse. However, abnormal protein folding 
during biosynthesis in the endoplasmic reticulum (ER) and subsequent ER-associated 
degradation (ERAD) is often observed.12 Ironically, many of the disease-associated mutant 
GCase forms are catalytically competent and able to process putative substrates at rates 
compatible with normal life, provided the unfolded protein response (UPR) leading to ERAD is 
bypassed.13-15 The use of pharmacological chaperones (PCs) to rescue the endogenous mutant 
enzyme by stabilizing the folding conformation and restoring trafficking represents, therefore, an 
interesting and, in principle, more general therapeutic option.16-18 Various classes of synthetic 
compounds have been studied as PCs for GD (Figure 1), including glycomimetics19 of the 
iminosugar (e.g. 1, 2),20,21 carbasugar (e.g. 3)22 and aminocyclitol (e.g. 4)23 families, amino sugar 
derivatives (e.g. 5, 6)24-26 and non-carbohydrate-related compounds identified after high-
throughput screening in drug repositioning programs (e.g. 7, 8).27,28 With few exceptions,29 most 
of these compounds proved active in enhancing GCase activity only in type 1 GD fibroblast 
cells, i.e., hosting the N370S mutation in homo- or heterozygosis. Aiming at addressing the 
neuronopathic forms of the disease, our laboratories developed a new family of PC candidates 
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based on very versatile amphiphilic sp2-iminosugar frameworks related to the natural alkaloids 
nojirimycin and castanospermine (e.g. 9, 10).30-32 The GCase rescuing mechanism was 
demonstrated in fibroblasts33 and in dopaminergic neurons (differentiated from induced 
pluripotent stem cells) of patients suffering from type 2 and 3 GD34 The chaperoning effect was, 
however, restricted to mutations located in the catalytic domain of the enzyme, which do not 
include the L444P homozygotes having the highest prevalence among neuropathic GD patients. 
 
Figure 1. Structures of representative iminosugar (1, 2), carbasugar (3), aminocyclitol (4), amino 
sugar (5, 6), non-glycomimetic (7, 8) and sp2-iminosugar (9-11) derivatives with 
pharmacological chaperone activity in Gaucher cells. 
Inspection of X-ray structural data of complexes between GCase and chaperones with either 
monocyclic20 or condensed bicyclic cores35,36 revealed that the sugar-like portion of the PC is 
distorted upon binding to the enzyme, the six-membered ring adopting an envelope or skew-boat 
conformation instead of the thermodynamically more stable chair conformation present in the 
unbound state. This induced-fit binding mechanism probably demands a very low 
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conformational effort from the protein side, confining the refolding potential of the PC to the 
regions near the catalytic site. We envisaged that chaperones encompassing an undistortable 
glycone moiety mimicking the glucose portion of GlcCer will instead force the protein to better 
adjust its conformation in order to form a tight-bound chaperone:GCase complex, thereby 
propagating the correct folding and stabilizing effects more efficiently beyond the catalytic 
domain. As a proof of concept, nor-tropane (calystegine)-based amphiphilic sp2-iminosugars 
(e.g. 11) were developed37,38 and found to exhibit unprecedented L444P/L444P GCase activity 
enhancing capabilities ex-vivo.39,40 As for the natural calystegine alkaloids, the bridged bicyclic 
core imparts selectivity towards GCase among lysosomal enzymes.41,42  Notably, replacing the 
basic amino groups by a neutral thiourea functionality with strong hydrogen-bond donor 
capabilities does not annul the glycosidase inhibitory/chaperoning potential, which is in 
agreement with observations in the nojirimycin glycomimetic series, and improves membrane-
crossing abilities.30,43 However, the incorporation of a hydrophobic N’-substituent is required to 
achieve biologically useful enzyme affinities.44  Interestingly, the presence of the ω-
hydroxyhexadecyl aglycone segment in compound 11 was particularly beneficial, which was 
ascribed to the interplay of hydrophobic interactions with amino acids at the entrance of the 
catalytic site of GCase and a long range hydrogen bond interaction (see SI, Figure S1).39 We now 
conceived that replacement of the terminal segment in the hydrocarbon tail by a polyfluorinated 
fragment might further favor complex stability and GCase rescuing capabilities by providing 
additional contacts with protein surfaces, a strategy that has proven very successful in medicinal 
chemistry schemes.45,46 
Fluoroalkylation of iminosugars has been found to increase affinity against some 
complementary glycosidases47-49 and is also expected to enhance biological membrane crossing 
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capabilities, including across the blood-brain barrier (BBB),50 which is critical in PC therapy 
addressing neuronopathic pathologies. The high tendency of amphiphilic polyfluorocompounds 
to form colloidal aggregates might represent a serious limitation for pharmaceutical use, 
decreasing the effective concentration of the free drug and thwarting a medically relevant 
result.51 Moreover, aggregation may lead to multivalent presentations of the PC motif, which 
may profoundly affect the affinity and selectivity profile towards protein partners.52,53 To avert  
these risks, here we capitalize on the high avidity of polyfluorinated amphiphiles towards the 
cavity of β-cyclodextrin (βCD)54 to prevent PC micellization (Figure 2).55 βCD is a 
commercially available biocompatible cyclooligosaccharide broadly used in the pharmaceutical 
industry to enhance the bioavailability of drugs by increasing their water solubility, avoiding 
aggregation and/or improving  drug permeability. Interestingly, βCD increases the membrane-
crossing capabilities of hydrophobic drugs hosted in the cavity, including penetration across the 
BBB,56  by making the single molecule drug available at the surface where it partitions into the 
membrane without disrupting the lipid layers of the barrier.57 The design and synthesis of the 
fluorinated pharmacological chaperone prototypes, the characterization of the corresponding 
inclusion complexes with βCD, the enzyme inhibition properties of the free and complexed 
chaperones and the GCase activity enhancement in GD cells hosting different mutations 
associated to neuronopathic variants of the disease are reported. 
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Figure 2. Schematic representation of the proposed strategy for Gaucher disease chaperone 
therapy based on fluorinated sp2-iminosugars with an undistortable 1,6-anhydro-L-
idonojirimycin core equipped with fluorinated aglycones. The high avidity of the fluorocarbon 
moiety towards the cavity of β-cyclodextrin should prevent micellization and favor the transfer 
of the chaperone to the active site of disease-causative misfolded glucocerebrosidase. Since the 
protein cannot distort the chaperone, it will be forced to adopt a properly folded conformation, 
which will be stabilized by additional interactions with the fluorinated segment. The properly 
folded enzyme will escape degradation at the ER and trafficking to the lysosome will be restored. 
Results and Discussion 
Design criteria and synthesis. Replacement of a hydrocarbon segment by a polyfluorocarbon 
moiety in the aglycone fragment of the chaperone implies an increase in chain rigidity that may 
hamper the capacity of the molecule to properly adapt to complementary surface regions in the 
protein, especially when considering allosteric interactions.58 To prevent such eventuality, we 
βCD
micellization
demicellization
chaperone:βCD
complex
misfoldedmutant
GCase
chaperone:mutantGcase
complex
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chose to insert a polymethylene portion between the undistortable nor-tropane aglycone core and 
the terminal fluorinated part (Figure 2). This molecular design is compatible with a modular 
synthetic approach involving: (i) an L-idose precursor of the glycomimetic scaffold that will 
provide the desired all-trans-equatorial glucose-like stereochemistry at the key triol segment, (ii) 
a bifunctional alkylidene derivative incorporating simultaneously an isothiocyanate group to 
generate the thiourea functionality, thereby imparting  the sp2-iminosugar feature, and a tert-
butoxycarbonyl (Boc)-protected amino group for additional conjugation, and (iii) a linear 
polyfluoroalkyl carboxylic acid suitable for chemoselective amide coupling with an amine-armed 
chaperone intermediate (Figure 3). 
 
Figure 3. General structure of the proposed chaperone prototype and retrosynthetic scheme with 
indication of the key building blocks. 
A divergent synthetic scheme was implemented that allows generating molecular diversity 
with a relatively low synthetic cost. Starting from 5-amino-5-deoxy-1,2-isopropylidene-L-
idofuranose (13), readily accessible from commercial D-glucuronolactone,59 thiourea coupling 
reaction with the bifunctional derivatives 13 and 14, with four and nine methylene groups, 
respectively, afforded the corresponding adducts 15 and 16. Acid-treatment promotes 
concomitant hydrolysis of the isopropylidene and Boc protecting groups. Upon neutralization 
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with Amberlite® IRA 68 (OH-) ion-exchange resin, intramolecular nucleophilic addition of the 
N-thiourea atom to the masked aldehyde group of the monosaccharide takes place, resulting in 
the furanose→piperidine rearrangement. The resulting reducing sp2-iminosugar spontaneously 
undergoes intramolecular glycosylation involving the primary hydroxyl group to give, in a single 
step and in excellent yield, the bicyclic 1,6-anhydro-L-idonojirimycin (AIJ) skeleton of 17 and 
18 already armed with a terminal amino group. After peptide conjugation with the carboxylic 
acid derivatives 19 and 20, a library of four AIJ derivatives, namely 21-24, endowed with 
aglycone-like moieties of different lengths and combinations of hydrocarbon and 
polyfluorocarbon segments was generated. 
Scheme 1. Synthesis of the 1,6-Anhydro-L-Idonojirimycin Incorporating Fluorinated 
Aglycone Substituents 21-24. 
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Aggregation and Inclusion Complex Formation with β-Cyclodextrin. The critical micellar 
concentrations (CMC) of compounds 21-24 were measured by the pyrene method.60 Briefly, the 
fluorescence intensity of the pyrene molecule experiences an abrupt increase when confined to 
the hydrophobic environment of a micelle as compared with bulk water, which can be detected in 
a classical fluorimetric titration experiment. CMC values of 393 µM (for 21), 31.6 µM (for 22), 
37.5 µM (for 23) and 15.0 µM (for 24) were thus obtained (see SI, Figures S19 to S22). Except 
for 21, these values are in the range of the concentrations encountered for optimal chaperone 
activity in cell cultures of patients suffering from lysosomal storage disorders with brain 
involvement, and in all cases are much lower than the chaperone concentrations needed to have a 
medically relevant result in vivo (over 1 mM).61 We, therefore, prepared and characterized the 
corresponding inclusion complexes with βCD prior to biological evaluation. 
The water solubility of all four fluorinated chaperones 21-24 was highly increased in the 
presence of βCD; no aggregation was observed at equimolecular chaperone:host ratios of up to 1 
mM.  For comparison, α-cyclodextrin (αCD) was unable to promote any significant water 
solubility enhancement, supporting the fact that the inclusion of the polyflurocarbon moiety in 
the βCD cavity is responsible for this observation. NMR titration experiments conducted with 
derivatives 21 and 22, sharing the tetramethylene segment, afforded binding isotherms fitting 1:1 
PC:βCD complexes (i.e., one molecule of βCD encapsulates a single molecule of the fluorinated 
chaperone),62 with association constant (Ka) values 7.5±0.7  · 103 M-1 and 3.4±0.3 · 104 M-1 (see 
Supporting Information, Figures S31 and S32). In the case of the homologs having the 
nonamethylene segment 23 and 24, the low water solubility of the chaperone prevented a parallel 
thermodynamic study by NMR. Nevertheless, formation of the corresponding inclusion 
complexes was equally supported by 1H NMR data in the presence of excess of βCD. Given that 
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the fluorinated moieties are identical in 21 or 23 and in 22 or 24, similar Ka values and the same 
1:1 complex stoichiometry would be expected. It is noteworthy that association constants of 
about 103-104 M-1 are in the optimal range for pharmaceutical formulations and warrant the 
efficient transfer of the chaperone from the inclusion complex to the target protein, for which the 
binding constant with sp2-iminosugar substrate analogs is typically in the 106-107 range.63 
Enzyme Inhibition Properties. In a preliminary assay, the inhibitory properties of compounds 
21-24 and their corresponding 1:1 complexes with βCD were assessed against a panel of 
commercial glycosidases covering a variety of configurational and anomeric specificities, 
including bovine and almond β-glucosidase, yeast α-glucosidase and isomaltase, Aspergillus 
niger amyloglucosidase, Escherichia coli β-galactosidase, green coffee bean α-galactosidase, 
Helix pomatia β-mannosidase, and Jack bean α-mannosidase (Table 1). Strong competitive 
inhibition (inhibition constant, Ki, values in the low µM-to-nM range) was exclusively observed 
against the mammalian β-glucosidase enzyme. Compounds 21 and 22 additionally behaved as 
weak inhibitors of the plant isoenzyme (Ki >100 µM). In any case, the configurational and 
anomeric selectivity towards β-glucosidase was outstanding: no inhibition of any of the other 
glycosidases was observed at sp2-iminosugar concentrations of up to 1 mM (uncomplexed) or 2 
mM (βCD complexes). 
Table 1. Ki Values (µM) for 21-24 and their 1:1 Complexes with βCD against 
Glycosidases.
a,b,c,d,e
 
Enzyme 21 21:βCD 22 22:βCD 23 23:βCD 24 24:βCD 
β-Glcase (bovine 
liver) 
6.4 ±0.2 1.3±0.1 1.1±0.1 0.13±0.02 0.34±0.03 0.26 0.33±0.05 2.5±0.1 
GCase (human, 
pH 5) 
20.8± 0.7 4.5±0.1 90±4 1.4±0.3 80±5 8.2±0.5 32.6±0.6 7.2±0.3 
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GCcase (human, 
pH 7) 
35±2 0.30 ±0.03 11.9±0.5 0.09±0.01 9.3±0.6 0.9±0.1 4.1±0.3 0.6±0.1 
aData are presented as mean±SD ( n = 3). bInhibition was competitive in all cases except for 
24:βCD against bovine liver β-glucosidase, which was mixed-type (uncompetitive component 
K’i = 2.6±0.1 µM). cNo inhibition was observed for any compound at 1 mM (free) or 2 mM 
concentration (βCD complexes) on baker’s yeast isomaltase, Aspergillus niger 
amyloglucosidase, green coffee bean α-galactosidase, Jack bean α-mannosidase and Helix 
pomatia β-mannosidase. dNo inhibition was observed for any compound at 200 µM on 
lysosomal α-glucosidase, α- and β-galactosidases, α- and β-mannosidases and hexosaminidase 
in cell lysates. eControl experiments using βCD at a 2 mM concentration in the absence of 21-24 
showed no inhibition at all for any of the assayed enzymes. 
Further assessment of the inhibition abilities of 21-24 against human lysosomal glycosidases in 
cell lysates (in vitro enzyme assay; see Experimental) confirmed the selectivity pattern 
previously observed for the commercial enzymes: whereas GCase was responsive to µM 
concentrations of the fluorinated sp2-iminosugars (Ki values in the range of 20-90 µM at pH 5; 3-
12 µM at pH 7), the activity of lysosomal α-glucosidase, α- and β-galactosidases, α- and β-
mannosidases and hexosaminidase was not affected at concentrations of up to 200 µM. 
Interestingly, the corresponding complexes of 21-24 with βCD behaved as stronger inhibitors of 
GCase than the free compounds, with Ki values in the low µM range at pH 5 and in the nM range 
at pH 7, suggesting that the enzyme is sensitive to inhibitor aggregation and that demicellization 
through inclusion complex formation improves GCase  binding affinity. This effect is 
particularly dramatic in the case of compound 22, for which the co-formulation with βCD led to 
66- (pH 5) and 126-fold (pH 7) enhancements in the inhibitory potency towards GCase (Table 
1). The above-ten-fold lower Ki values at neutral pH (0.09 to 0.9 µM) as compared to acidic pH 
(1 to 7 µM) is generally considered as a positive feature for chaperone candidates: it means that 
the compound will bind stronger to GCase at the ER, where stabilization of the correct folding is 
required, than at the lysosome, where dissociation of the chaperone:GCase complex is necessary 
to allow substrate processing. 
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Chaperoning Capabilities of Fluorinated sp2-Iminosugar:βCD Complexes in Gaucher 
Fibroblasts. The effects of the new fluorinated sp2-iminosugars 21-24 and their inclusion 
complexes with βCD on GCase activity and cell viability were first investigated in healthy 
human fibroblasts. For that purpose, cells were cultured for 5 days in the absence and in the 
presence of various concentrations of the compounds, then lysed and the enzyme activity was 
determined using 4-methylumbelliferyl β-D-glucopyranoside as substrate. An enhancement in the 
measured GCase activity in the lysate indicates that larger amounts of the protein are present and 
that it is able to process the substrate. In this sense, it is worth mentioning that although GCase 
inhibition is generally considered a valuable indication for PC drug candidates, a higher 
inhibitory potential does not necessarily translate into a better performance as a PC. If 
displacement of the inhibitor from the enzyme:inhibitor complex is strongly disfavored, the  
enzyme would not be functional even though the compound may restore the proper folding and 
trafficking of mutant GCase variants.64 
Compounds 21 and 23, bearing a perfluorobutyl terminal moiety, had no significant effect 
neither on GCase activity nor on cell viability at concentrations of up to 100 µM (data not 
shown), neither in free form nor when complexed with βCD.  However, the corresponding 
homologs 22 and 24, with a perfluorohexyl moiety, decreased GCase activity by 30-50% at a 
concentration of 20 µM and induced a cell death of 45-75% at 100 µM when used in their 
uncomplexed form (see SI, Table S1). Both GCase inhibition and cell mortality were abolished 
when the compounds were formulated with βCD in the concentration window of interest, 
strongly suggesting that aggregation of the free fluorinated amphiphiles was responsible for these 
observations.  
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The fluorinated sp2-iminosugar (21-24):βCD complexes, showing no aggregation-related 
adverse effects, were further evaluated with regard to the GCase activity enhancement in 
Gaucher fibroblasts from patients hosting the N370S/N370S, N370S/84GG (non-neuronopathic, 
type 1 GD), V230G/R296X, L444P/P415R (acute neuronopathic, type 2 GD), N188S/G183W or 
L444P/L444P mutations (neuronopathic, type 3 GD), following the aforementioned protocol for 
healthy fibroblasts (Table 2). The results, collectively presented in Figure 4, which represent 
mean values from three independent experiments, each carried out in triplicate, evidenced 
significant differences as a function of both the GD causative mutation and the chaperone 
formulation. 
Table 2. Characteristics of the GCase variants assayed in this study. 
GCase  variant Location Severity Responsiveness to PC therapy 
NN-DNJ (1) / ambroxol (7)a 
N370S/N370S Domain III Type 1 GD + / + 
N370S/84GG Domain III Type 1 GD + / + 
V230G/R296X Domain III Type 2 GD −b / + 
L444P/P415R Domain II Type 2 GD − / +c 
N188S/G183W Domain II Type 3 GD + / + 
L444P/L444P Domain II Type 3 GD −d / +c 
aThe + and – signs indicate responsive and not responsive, respectively. bResponsive to the 
acid-sensitive sp2-iminosugar 9. cMedically useful activity enhancements are only reached at 
relatively high concentrations (>50 µM). dResponsive to calystegine-type sp2-iminosugar 11. 
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Figure 4. Chaperone activity of 21-24:βCD complexes in cultured human fibroblasts of type 1 
(N370S/N370S and N370S/84GG), type 2 (V230G/R296X and L444P/P415R), and type 3 
(N188S/G183W) Gaucher patients. Each bar represents the mean±standard error (SEM) of 3 
determinations each done in triplicate. Control experiments conducted with βCD in the absence 
of 21-24 showed no effect in GCase activity for any of the mutants. *p < 0.05, statistically 
different from the value of untreated samples. #p < 0.05, statistically different from the value 
obtained for the precedent ten-fold lower concentration of the PC:βCD complex. 
The non-neuronopathic homozygous N370S mutation, the most prevalent in type 1 GD 
patients, was moderately responsive to treatment with 22:βCD (1.5-fold GCase activity 
enhancement at a concentration of 2 µM), in line with results obtained with other sp2-
iminosugars30,32 but considerably weaker when compared to other glycomimetic-type 
candidates.19,21-23 The other three fluorinated sp2-iminosugar formulations behaved very poor or 
were inactive as chaperones in the same cell assay. Indeed, structural and biochemical data 
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indicated that the protein is already correctly folded in N370S/N370S GD patients and that the 
mechanism by which some protonable competitive inhibitors increase the lysosomal levels of 
GCase is by reducing degradation by means of proteases within the lysosome, rather than by 
having an effect on protein folding and trafficking;65 neutral sp2-iminosugars are instead 
designed to assist folding at the ER but dissociate from the protein at the lysosome.19 The second 
type 1 GD mutation evaluated in this study, namely N370S/84GG, was much more sensitive to 
chaperoning by the fluorinated sp2-iminosugar:βCD complexes, with GCase activity 
enhancements with approx. 1.5- to 1.7-fold GCase activity enhancements for 21:βCD, 23:βCD 
and 24:βCD and reaching 2.8-fold for 22:βCD ad 20 µM. 
The acute-neuronopathic (early onset) type 2 GD-associated mutations V230G/R296X and 
L444P/P415R are located in the catalytic and in the non-catalytic domain of GCase, namely 
domains III and II, respectively.19,66 The first was previously found to respond only very 
modestly to sp2-iminosugars with distortable cores,64 unless equipped with a pH-sensitive 
mechanism ensuring full dissociation in the lysosome (e.g. 9, Figure 1).30 Those glycomimetics 
are, however, not effective in fibroblast of GD patients hosting domain II-located mutations. To 
the best of our knowledge, the only documented example of a chaperone effect in the 
L444P/P415R GCase variant reports a 1.5-fold activity enhancement using 4-[(2-amino-3,5-
dibromophenyl)methylamino]cyclohexan-1-ol (ambroxol; 7, Figure 1) at a concentration of 50 
µM.67 In the present study, the βCD formulation with compound 21, bearing the shortest 
aglycone substituent, displayed the highest chaperone effect in V230G/R296X GD fibroblasts 
among the series (2.7-fold GCase activity enhancement at 20 µM). Compound 22, differing only 
in a tetrafluoromethylene segment, also promoted a significant GCase activity enhancement (1.8-
fold at 20 µM), whereas the homologs 23 and 24, in which the hydrocarbon moiety increases 
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from four to nine methylene groups, were inactive. Remarkably, the very severe GD 
L444P/P415R mutation responded to the four fluorinated sp2-iminosugar (21-24):βCD 
complexes, with a 1.7- to 1.9-fold increased activity for 21, 23 and 24 and of up to 2.9-fold in the 
case of the 22:βCD formulation at 20 µM. 
The adult neuronopathic type 3 GD-associated N188S/G183W mutation is located in the 
catalytic domain (domain III) and has previously been found to be reactive to sp2-iminosugars 
with distortable cores such as 9 or 10 (Figure 1).30,32 In stark contrast, the homozygous L444P 
variant, having the highest prevalence among neuronopathic GD patients, has been found to 
respond only to undistortable sp2-iminosugars such as 22 (Figure 1), with mutant GCase activity 
enhancements being 1.6-fold at a chaperone concentration of 2-25 µM.39 A similar result was 
obtained with the new fluorinated sp2-iminosugars 21 and 24 in complex with βCD when 
administered at 20 µM. The 22:βCD formulation performed outstandingly better in this variant, 
reaching an unprecedented 2-fold mutant enzyme activity enhancement at a concentration of 
only 2 µM and increasing to 2.8-fold at 20 µM. 
The results above discussed highlight the potential of the strategy based on the use of 1,6-
anhydro-L-idonojirimycin undistortable glycomimetics with fluorinated aglycones, in complex 
with β-cyclodextrin, to develop a chaperone therapy against the neuronopathic forms of Gaucher 
disease, including highly challenging domain II-located GCase mutations. However, note that the 
widely investigated piperidine-type GCase inhibitor N-nonyl-1-deoxynijirimycin (NN-DNJ; 1, 
Figure 1), which is able to enhance N370S GCase activity by 65% and is frequently used as a 
reference pharmacological chaperone for GD, did not show any activity in the L444P GCase 
mutant in our work not in that of others.32,68  In order to confirm that the mechanism of action 
involves rescuing and trafficking restoration of the endogenous mutant GCase, immunolabeling 
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and colocalization experiments were further conducted using fibroblasts from type 2 GD patients 
bearing the L444P/P415R mutation (Figure 5). The left panel shows a series of confocal 
fluorescence microscopy images after immunostaining of the ER (protein disulfide isomerase, 
PDI; red), GCase (green) and the nucleus (Hoechst; blue), as well as the corresponding merged 
images, in healthy control fibroblasts and in L444P/P415R GD fibroblasts before and after 
treatment with 22:βCD at 20 µM. It can be observed that the GCase content in the cells of GD 
patients is much lower than in the control and that it colocalizes with the ER (yellow spots), in 
agreement with impaired traffic to the lysosome. After treatment with the chaperone:βCD 
complex, the amount of GCse increases very significantly and it is no longer located in the ER. 
The right panel, in which the lysosome (lysosome associated membrane protein 2, LAMP-2; 
red), instead of the ER, has been labeled, shows that after treatment with the chaperone, GCase 
colocalizes with this organelle as it happens in the control cells. Although full validation will 
require in situ GCase activity measurements,69,70 this result complements the in vitro assays and 
strongly supports that the observed enzyme activity enhancements correspond indeed to the 
lysosomal and not to the cytoplasmatic GCase component.32,33  
 
Figure 5. Effect of 22:βCD on the traffic of GCase from the ER to lysosomes in L444P/P415R 
type 2 Gaucher fibroblasts. Fibroblasts were treated with 20 µM of the complexed chaperone. 
Page 18 of 50
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 19
Left panel: ER marker (protein disulfide isomerase, PDI) or GCase are visualized as red or 
green, respectively; in the merged images, yellow denotes colocalization in the ER. Right panel: 
lysosomal marker (lysosome associated membrane protein 2, LAMP-2) or GCase are visualized 
as red or green, respectively; in the merged images, yellow denotes colocalization in lysosomes. 
Scale bar = 15 µm. The shown pictures are representative of more than 100 cells in 10 randomly 
obtained images. 
Chaperone-GCase Docking Experiments. Although the responsiveness of mutant GCase to 
chaperone therapy is clearly patient-dependent, the set of the results indicates that the fluorinated 
sp2-iminosugar 22 has a remarkably broader activity profile when compared to the other 
compounds in the series, being able to promote very significant enzyme activity enhancements in 
GCase variants bearing mutations in any of the three protein domains, including the highly 
refractory domain II-located L444P/P415R and L444P/L444P mutants. In order to obtain 
structural information on the interactions operating in chaperone:GCase complex stabilization, 
binding of 22 to GCase was studied next by means of docking and MD simulations. The bicyclic 
core binds to the active site, with the hydroxyl groups involved in a hydrogen-bonding network 
with the surrounding amino acids (Asn127, Asn234, Arg395). Contrary to the observations for 
other amphiphilic GCase ligands, the N-substituent does not locate above the hydrophobic 
channel at the entrance of the active site, but turns instead to the catalytic site area establishing a 
number of fluor-aromatic contacts (Figure 6). The resulting very compact arrangement was 
stable along the 20 ns MD trajectory computed. This is in agreement with the observed strong 
influence of structural modifications in the hydrocarbon or perfluorocarbon segments related to 
the chaperoning capabilities of the PC, probably being responsible for the unprecedented broad 
mutation-range GCase rescuing capabilities of 22. 
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Figure 6. Docking of 22 to the human β-glucocerebrosidase structure (see Experimental Section 
for details). A) View of the enzyme surface showing the active site; the docked molecule is 
represented by sticks. B) Detail of the active site cavity, with the docked molecule inside (carbon 
in green, fluor in light green, nitrogen in blue, oxygen in red, sulfur in yellow, hydrogen in white; 
hydrogen atoms linked to carbon are omitted for clarity). Amino acid residues in closest contact 
with the chaperone are also depicted. C) Diagram showing the interactions between the protein 
and the ligand. Images correspond to the MD snapshot closest to the average structure. 
Conclusions 
The set of results discussed herein provides solid proof of the concept concerning the 
suitability of the sp2-iminosugar prototype based on AIJ undistortable glycomimetics with 
fluorinated substituents, fitting in the GCase active site, for the development of PC candidates 
targeting the neuronopathic forms of Gaucher disease. Formulation of the fluorinated PC with β-
cyclodextrin prevents unwanted side effects arising from aggregation while warranting the 
efficient transfer of the drug to the enzyme in the ER, thereby bypassing the UPR and restoring 
trafficking to the lysosome, as confirmed by immunolabeling and colocalization studies. 
Docking experiments underlined the importance of fine-tuning the flexibility of the molecule to 
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optimize the contacts between the fluorinated portion and the protein in order to achieve high 
activity enhancements for a broad range of GD causative single nucleotide GCase polymorphs. 
Since other lysosomal glycosidases also have lipophilic pockets with aromatic amino acids in the 
vicinity of the catalytic site,19 the incorporation of fluorinated moieties onto glycomimetic 
scaffolds showing stereocomplementarity with the putative sugar substrates can be generalized 
for the design of PCs targeting a range of LSDs. Interestingly, UPR-inducing mutations in 
GCase, even when asymptomatic for GD, represent the strongest risk factor for developing 
Parkinson disease (PD) hitherto identified.71,72 Indeed, the possibility of using PCs for 
neuroprotection therapy in PD has already been confirmed in mutant mice and in PD 
fibroblasts73 and neurons,74 further highlighting the importance of developing efficient strategies 
for PC optimization. Further studies on the potential of fluorinated sp2-iminosugars in 
formulation with cyclodextrins to tackle both LSDs and PD are currently being carried out in our 
laboratories. 
 
Experimental Section 
General Methods. Reagents and solvents were purchased from commercial sources and used 
without further purification. Optical rotations were measured with a JASCO P-2000 polarimeter, 
using a sodium lamp (λ = 589 nm) at 22 ºC in 1 cm or 1 dm tubes. IR spectra were recorded on a 
JASCO FTIR-410 device. UV spectra were recorded on JASCO V-630 instrument; unit for ε 
values: mM-1cm-1. NMR experiments were performed at 300 (75.5), 400 (100.6) and 500 (125.7) 
MHz. 1-D TOCSY as well as 2-D COSY and HMQC experiments were carried out to assist 
signal assignment. In the FABMS spectra, the primary beam consisted of Xe atoms with a 
maximun energy of 8 keV. The samples were dissolved in m-nitrobenzyl alcohol or thioglycerol 
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as the matrices and the positive ions were separated and accelerated above a potencial of 7 keV. 
NaI was added as cationizing agent. For ESI mass spectra, 0.1 pM sample concentrations were 
used, the mobile phase consisting of 50% aq MeCN at 0.1 mL min-1. Thin-layer chromatography 
was performed on precoated TLC plates, silica gel 30F-245, with visualization by UV light and 
also with 10% H2SO4 or 0.2% w/v cerium (IV) suphate-5% ammonium molybdate in 2 M H2SO4 
or 0.1% ninhydrin in EtOH. Column chromatography was performed on Chromagel (silice 60 
AC.C 70-200 µm). All compounds were purified to ≥95% purity as determined by elemental 
microanalysis results obtained on a CHNS-TruSpect® Micro elemental analyzer (Instituto de 
Investigaciones Químicas de Sevilla, Spain) from vacuum-dried samples. The analytical results 
for C, H, N and S were within ±0.5 of the theoretical values. 
Materials. 4-(tert-Butoxycarbonylamino)butyl isothiocyanate, 4,4,5,5,6,6,7,7,7-
nonafluoroheptanoic acid, and 4,4,5,5,6,6,7,7,8,8,9,9,9-tridecafluorononanoic acid were 
purchased from commercial sources. N-(tert-Butoxycarbonyl)nonanediamine75 and 5-amino-5-
deoxy-1,2-O-isopropylidene-β-L-idofuranose59 (12) were synthesized using the previously 
described routes. 
9-(tert-Butoxycarbonylamino)nonyl Isothiocyanate (14). CSCl2 (0.87 mL, 11.4 mmol) was 
added to a heterogeneous mixture of N-(tert-butoxycarbonyl)nonanediamine75 (737 mg, 2.85 
mmol) in 1:1 DMC-H2O (32 mL) and CaCO3 (2.3 g, 23 mmol), CSCl2 (0.87 mL, 11.4 mmol) 
was added at 0 ºC. The reaction mixture was vigorously stirred for 2 h at rt and the organic phase 
was separated. The aqueous phase was extracted with DCM (3 x 15 mL), the combined extracts 
were dried (MgSO4), concentrated, and the resulting residue was purified by column 
chromatography (1:8→1:4 EtOAc-petroleum ether). Yield: 599 mg (56%). Rf 0.50 (1:4 EtOAc-
petroleum ether). IR (ATR) νmax 2177 cm-1. 1H NMR (300 MHz, CDCl3) δ 4.50 (bs, 1 H, NH), 
Page 22 of 50
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 23
3.50 (t, 2 H, 3JH,H = 6.6 Hz, CH2NCS), 3.09 (m, 2 H, CH2NHCO), 1.68 (m, 2 H, CH2), 1.45 (s, 9 
H, CMe3), 1.39 (m, 12 H, CH2). 13C NMR (125.7 MHz, CDCl3) δ 156.0 (CO), 129.9 (NCS), 79.0 
(CMe3), 45.0 (CH2NCS), 40.6 (CH2NHCO), 30.0 29.9, 29.3, 29.1, 28.7 (CH2), 28.4 (CMe3), 
26.7, 26.5 (CH2). ESIMS: m/z 323 [M + Na]+. Anal. Calcd for C15H28N2O2S: C, 59.96; H, 9.39; 
N, 9.32; S, 10.67. Found: C, 60.09; H, 9.43; N, 9.24; S, 10.48. 
5-[N’-(4-tert-Butoxycarbonylaminobutyl)thioureido]-5-deoxy-1,2-O-isopropylidene-β-L-
idofuranose (15). Et3N (0.6 mL, 4.3 mmol) and isothiocyanate 13 (0.94 mmol, 1.1 eq) were 
added to a solution of 5-amino-5-deoxy-1,2-O-isopropylidene-β-L-idofuranose59 (12, 188 mg, 
0.86 mmol) in pyridine (5 mL). The mixture was stirred at rt for 18 h and concentrated. The 
resulting residue was coevaporated several times with toluene and purified by column 
chromatography using 50:1 → 40:1 DCM-MeOH as the eluent. Yield: 317 mg (82%; colorless 
syrup). [α]D −68.4 (c 1.0 in DCM). Rf 0.22 (100:10:1 DCM-MeOH-H2O). UV (DCM) 242 nm 
(εmM 14.1). 1H NMR (500 MHz, CD3OD, 323 K) δ 5.98 (d, 1 H, J1,2 = 3.7 Hz, H-1), 4.66 (m, 1 
H, H-5), 4.58 (d, 1 H, H-2), 4.39 (dd, 1 H, J4,5 = 7.8 Hz, J3,4 = 2.6 Hz, H-4), 4.22 (d, 1 H, H-3), 
3.83 (dd, 1 H, J6a,6b = 11.2 Hz, J5,6a = 4.3 Hz, H-6a), 3.80 (dd, 1 H, J5,6b = 4.8 Hz, H-6b), 3.57 (m, 
2 H, CH2NHCS), 3.15 (m, 2 H, 3JH,H = 6.7 Hz, CH2NHBoc), 1.68 (m, 2 H, CH2), 1.60 (m, 2 H, 
CH2), 1.54, 1.38 (2 s, 6 H, CMe2), 1.52 (s, 9 H, CMe3), 1.37 (m, 4 H, CH2). 13C NMR (125.7 
MHz, CD3OD, 323 K) δ 183.7 (CS), 158.5 (CO), 112.8 (CMe2), 105.8 (C-1), 87.0 (C-2), 81.2 
(C-4), 80.0 (CMe3), 75.8 (C-3), 62.7 (C-6), 56.2 (C-5), 45.1 (CH2NHCS), 41.1 (CH2NHBoc), 
28.8 (CMe3), 28.3, 27.5 (CH2), 27.0, 264 (CMe2). ESIMS: m/z 472 [M + Na]+. Anal. Calcd for 
C19H35N3O7S: C, 50.76; H, 7.85; N, 9.35; S, 7.13. Found: C, 50.74; H, 7.60; N, 9.57; S, 6.97. 
5-[N’-(9-tert-Butoxycarbonylaminononyl)thioureido]-5-deoxy-1,2-O-isopropylidene-β-L-
idofuranose (16). Et3N (0.6 mL, 4.3 mmol) and isothiocyanate 14 (0.94 mmol, 1.1 eq) were 
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added to a solution of 5-amino-5-deoxy-1,2-O-isopropylidene-β-L-idofuranose59 (12, 188 mg, 
0.86 mmol) in pyridine (5 mL). The mixture was stirred at rt for 18 h and concentrated. The 
resulting residue was coevaporated several times with toluene and purified by column 
chromatography using 30:1→15:1 CH2Cl2-MeOH as the eluent. Yield: 286 mg (64%; white 
amorphous solid). [α]D −58.8 (c 1.0 in DCM). Rf 0.40 (15:1 DCM-MeOH). UV (DCM) 248 nm 
(εmM 14.1). 1H NMR (500 MHz, CDCl3, 313 K) δ 6.65 (bs, 1 H, NH), 5.99 (d, 1 H, J1,2 = 3.7 Hz, 
H-1), 4.84 (bs, 1 H, H-5), 4.60 (bs, 1 H, NH), 4.54 (d, 1 H, H-2), 4.32 (d, 1 H, J3,4 = 2.1 Hz, H-
3), 4.29 (m, 1 H, H-4), 4.22 (bs, 1 H, NH), 3.92 (dd, 1 H, J6a,6b = 11.2 Hz, J5,6a = 4.6 Hz, H-6a), 
3.76 (dd, 1 H, J5,6b = 5.4 Hz, H-6b), 3.41 (bs, 2 H, CH2NHCS), 3.30 (bs, 1 H, OH), 3.11 (m, 2 H, 
CH2NHBoc), 19.1 (bs, 1 H, OH), 1.58 (m, 2 H, CH2CH2NHCS), 1.52, 1.33 (2 s, 6 H, CMe2), 
1.50 (m, 2 H, CH2), 1.46 (s, 9 H, CMe3), 1.32 (m, 10 H, CH2). 13C NMR (125.7 MHz, CDCl3, 
313 K) δ 182.1 (CS), 156.2 (CO), 111.9 (CMe2), 104.6 (C-1), 85.0 (C-2), 80.5 (C-4), 79.2 
(CMe3), 75.4 (C-3), 63.9 (C-6), 54.9 (C-5), 44.7 (CH2NHCS), 40.6 (CH2NHBoc), 29.9, 29.2, 
28.9, 28.8, 28.7 (CH2), 28.5 (CH2, CMe3), 26.8, 26.1 (CMe2), 26.7 (CH2). ESIMS: m/z 542 [M + 
Na]+. Anal. Calcd for C24H45N3O7S: C, 55.47; H, 8.73; N, 8.09; S, 6.17. Found: C, 55.41; H, 
8.71; N, 8.08; S, 6.03. 
N-[N’-(4-Aminobutyl)thiocarbamoyl]-1,6-anhydro-α-L-idonojirimycin Hydrochloride 
(17). A solution of 15 (0.52 mmol) in 90% TFA-H2O (3 mL) was stirred at rt for 30 min, 
concentrated under reduced pressure, coevaporated several times with water, neutralized with 
Amberlite IRA-68 (OH-) ion-exchange resin, and subjected to column chromatography using 
6:1:1→6:2:1 CH3CN-H2O-NH4OH as the eluent. The product thus obtained was dissolved in 
water, HCl 0.1 M was added to until pH 5.0, and the resulting solution was freeze-dried. Yield: 
141 mg (93%; white foam). [α]D +41.5 (c 1.0 in MeOH). Rf 0.25 (6:3:1 CH3CN-H2O-NH4OH). 
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UV (H2O) 242 nm (εmM 16.2). 1H NMR (500 MHz, D2O, 323 K) δ 6.13 (s, 1 H, H-1), 5.05 (m, 1 
H, H-5), 4.34 (d, 1 H, J6a,6b = 8.5 Hz, H-6a), 4.05 (dd, 1 H, J5,6b = 5.0 Hz, H-6b), 3.94 (m, 1 H, 
H-4), 3.81 (m, 4 H, H-2, H-3, CH2NHCS), 3.00 (t, 2 H, JH,H = 7.3 Hz, CH2NH2), 1.85 (m, 2 H, 
CH2), 1.77 (m, 2 H, CH2). 13C NMR (125.7 MHz, D2O, 323 K) δ 178.0 (CS), 88.8 (C-1), 75.7 
(C-3), 74.0 (C-2), 71.0 (C-4), 66.6 (C-6), 58.9 (C-5), 45.5 (CH2NHCS), 40.5 (CH2NH2), 27.5, 
26.7 (CH2). ESIMS: m/z 292 [M + H]+. Anal. Calcd for C11H22ClN3O4S: C, 40.30; H, 6.76; N, 
12.82; S, 9.78. Found: C, 40.65; H, 6.47; N, 12.58; S, 9.55. 
N-[N’-(9-Aminononyl)thiocarbamoyl]-1,6-anhydro-α-L-idonojirimycin Hydrochloride 
(18). A solution of 16 (0.52 mmol) in 90% TFA-H2O (3 mL) was stirred at rt for 30 min, 
concentrated under reduced pressure, coevaporated several times with water, neutralized with 
Amberlite IRA-68 (OH-) ion-exchange resin, and subjected to column chromatography using 
10:1 CH3CN-H2O as the eluent. The product thus obtained was dissolved in water, HCl 0.1 M 
was added to until pH 5.0, and the resulting solution was freeze-dried. Yield: 160 mg (85%; 
white foam). [α]D +41.6 (c 1.0 in MeOH). Rf 0.27 (10:1:1 CH3CN-H2O-NH4OH). UV (MeOH) 
249 nm (εmM 14.6). 1H NMR (500 MHz, D2O, 313 K) δ 6.05 (s, 1 H, H-5), 4.96 (dd, 1 H, J1,7b = 
5.0 Hz, J1,2 = 4.1 Hz, H-1), 4.25 (d, 1 H, J7a,7b = 8.5 Hz, H-6a), 3.96 (dd, 1 H, H-6b), 3.85 (dd, 1 
H, J2,3 = 8.4 Hz, H-2), 3.73 (m, 2 H, H-4, H-3), 3.69 (td, 2 H, JH,H = 7.1 Hz, JCH,NH = 3.4 Hz, 
CH2NHCS), 3.09 (t, 2 H, JH,H = 7.5 Hz, CH2NH2), 1.73 (m, 4 H, CH2), 1.45 (m, 14 H, CH2). 13C 
NMR (125.7 MHz, D2O, 313 K) δ 177.5 (CS), 88.5 (C-5), 75.2 (C-3), 74.07 (C-4), 70.8 (C-2), 
66.2 (C-7), 58.4 (C-1), 45.6 (CH2NHCS), 39.8 (CH2NH2), 28.5, 28.4, 28.2, 26.8, 26.0, 25.7 
(CH2). FABMS: m/z 384 (90, [M + Na]+), 362 (20, [M + H]+). HRFABMS Calcd for 
C16H31N3O4S [M + Na]+ 384.1933, found 384.1925. 
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N-[N’-[4-(4,4,5,5,6,6,7,7,7-Nonafluoroheptanamido)butyl]thiocarbamoyl]-1,6-anhydro-α-
L-idonojirimycin (21). TBTU (79 mg, 0.25 mmol) and DIEA (162 µL, 0.95 mmol) were added 
to a solution of the amine 17 (0.25 mmol) and the carboxylic acid 19 (0.19 mmol) in DMF (10 
mL), under Ar atmosphere. The reaction mixture was stirred at rt for 18 h and the solvent was 
removed under reduced pressure. The resulting residue was purified by column chromatography 
using 100:10:0.5→70:10:0.5→50:10:0.5 DCM-MeOH-NH4OH as the eluent. Yield: 75 mg 
(70%; white amorphous solid). [α]D +24.3 (c 1.0 in MeOH). Rf 0.44 (45:5:3 EtOAc-EtOH-H2O). 
UV (MeOH) 249 nm (εmM 7.9). 1H NMR (500 MHz, CD3OD) δ 5.82 (bs, 1 H, H-1), 4.88 (m, 1 
H, H-5), 4.09 (d, 1 H, J6a,6b = 7.8 Hz, H-6a), 3.75 (dd, 1 H, J5,6b = 5.1 Hz, H-6b), 3.63 (m, 3 H, 
H-4, CH2NHCS), 3.54 (m, 2 H, H-2, H-3), 3.23 (m, 2 H, CH2NHCO), 2.52 (m, 4 H, CH2CO, 
CH2CF2), 1.66 (m, 2 H, CH2), 1.55 (m, 2 H, CH2). 13C NMR (125.7 MHz, CD3OD) δ 180.8 
(CS), 172.8 (CO), 90.2 (C-1), 77.4 (C-3), 75.8 (C-2), 72.4 (C-4), 66.8 (C-6), 60.0 (C-5), 45.9 
(CH2NHCS), 40.3 (CH2NHCO), 27.8, 27.6, 27.3 (CH2). ESIMS: m/z 565.5 [M + Na]+. Anal. 
Calcd for C18H24F9N3O5S: C, 38.23; H, 4.28; N, 7.43; S, 5.67. Found: C, 38.09; H, 4.53; N, 7.19; 
S, 5.31. 
N-[N’-[4-(4,4,5,5,6,6,7,7,8,8,9,9,9-Tridecafluorononanamido)butyl]thiocarbamoyl]-1,6-
anhydro-α-L-idonojirimycin (22). Compound 22 was obtained from amine 17 (0.25 mmol) and 
carboxylic acid 20 (0.19 mmol) following the procedure described above for 21. Column 
chromatography, eluent 100:10:0.5 →70:10:0.5→40:10:0.5 DCM-MeOH-NH4OH. Yield: 97 mg 
(77%; white amorphous solid). [α]D +33.4 (c 1.0 in MeOH). Rf 0.39 (45:5:3 EtOAc-EtOH-H2O). 
UV (MeOH) 248 nm (εmM 9.0). 1H NMR (400 MHz, CD3OD) δ 5.84 (bs, 1 H, H-1), 4.88 (m, 1 
H, H-5), 4.12 (d, 1 H, J6a,6b = 7.9 Hz, H-6a), 3.77 (dd, 1 H, J5,6b = 5.1 Hz, H-6b), 3.65 (m, 3 H, 
H-4, CH2NHCS), 3.57 (m, 2 H, H-2, H-3), 3.25 (t, 2 H, JH,H = 7.0 Hz, CH2NHCO), 2.54 (m, 4 H, 
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CH2CO, CH2CF2), 1.68 (m, 2 H, CH2), 1.58 (m, 2 H, CH2). 13C NMR (100.6 MHz, CD3OD) δ 
180.8 (CS), 172.7 (CO), 90.2 (C-1), 77.3 (C-3), 75.8 (C-2), 72.4 (C-4), 66.8 (C-6), 60.0 (C-5), 
45.9 (CH2NHCS), 40.3 (CH2NHCO), 27.8, 27.6, 27.3 (CH2). ESIMS: m/z 664.2 [M - H]-. Anal. 
Calcd for C20H24F13N3O5S: C, 36.10; H, 3.64; N, 6.31; S, 4.82. Found: C, 35.87; H, 3.93; N, 
6.33; S, 4.58. 
N-[N’-[4-(4,4,5,5,6,6,7,7,7-Nonafluoroheptanamido)nonyl]thiocarbamoyl]-1,6-anhydro-α-
L-idonojirimycin (23). Compound 23 was obtained from amine 18 (0.25 mmol) and carboxylic 
acid 19 (0.19 mmol) following the procedure described above for 21. Column chromatography, 
eluent 100:10:0.5→70:10:0.5→40:10:0.5 DCM-MeOH-NH4OH. Yield: 87 mg (72%; white 
amorphous solid). [α]D +27.7 (c 1.0 in MeOH). Rf 0.64 (45:5:3 EtOAc-EtOH-H2O). UV (MeOH) 
248 nm (εmM 9.8). 1H NMR (500 MHz, CD3OD) δ 5.85 (bs, 1 H, H-1), 4.90 (m, 1 H, H-5), 4.12 
(d, 1 H, J6a,6b = 7.9 Hz, H-6a), 3.77 (dd, 1 H, J5,6b = 5.1 Hz, H-6b), 3.70 (m, 1 H, H-4), 3.61 (m, 2 
H, CH2NHCS) 3.58 (m, 2 H, H-2, H-3), 3.21 (t, 2 H, JH,H = 7.1 Hz, CH2NHCO), 2.54 (m, 4 H, 
CH2CO, CH2CF2), 1.65 (m, 2 H, CH2), 1.53 (m, 2 H, CH2), 1.37 (m, 10 H, CH2). 13C NMR 
(125.7 MHz, CD3OD) δ 180.8 (CS), 172.6 (CO), 90.2 (C-1), 77.4 (C-3), 75.8 (C-2), 72.5 (C-4), 
66.8 (C-6), 60.1 (C-5), 46.5 (CH2NHCS), 40.6 (CH2NHCO), 30.5, 30.3, 30.3, 29.9, 27.9, 27.8, 
27.7 (CH2). ESIMS: m/z 658.4 [M + Na]+. Anal. Calcd for C23H34F9N3O5S: C, 43.46; H, 5.39; N, 
6.61; S, 5.04. Found: C, 43.37; H, 5.66; N, 6.49; S, 4.89. 
N-[N’-[4-(4,4,5,5,6,6,7,7,8,8,9,9,9-Tridecafluorononanamido)nonyl]thiocarbamoyl]-1,6-
anhydro-α-L-idonojirimycin (24). Compound 24 was obtained from amine 18 (0.25 mmol) and 
carboxylic acid 20 (0.19 mmol) following the procedure described above for 21. Column 
chromatography, eluent 100:10:0.5→70:10:0.5→40:10:0.5 DCM-MeOH-NH4OH. Yield: 119 
mg (85%; white amorphous solid). [α]D +22.8 (c 1.0 in MeOH). Rf 0.63 (45:5:3 EtOAc-EtOH-
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H2O). UV (MeOH) 249 nm (εmM 13.1). 1H NMR (500 MHz, CD3OD) δ 5.85 (bs, 1 H, H-1), 4.90 
(m, 1 H, H-5), 4.12 (d, 1 H, J6a,6b = 7.9 Hz, H-6a), 3.77 (dd, 1 H, J5,6b = 5.2 Hz, H-6b), 3.68 (m, 1 
H, H-4), 3.61 (m, 2 H, CH2NHCS), 3.58 (m, 2 H, H-2, H-3), 3.21 (t, 2 H, JH,H = 7.1 Hz, 
CH2NHCO), 2.54 (m, 4 H, CH2CO, CH2CF2), 1.65 (m, 2 H, CH2), 1.54 (m, 2 H, CH2), 1.37 (m, 
10 H, CH2). 13C NMR (125.7 MHz, CD3OD) δ 180.9 (CS), 172.7 (CO), 90.2 (C-1), 77.4 (C-3), 
75.9 (C-2), 72.5 (C-4), 66.8 (C-6), 60.1 (C-5), 46.5 (CH2NHCS), 40.6 (CH2NHCO), 30.6, 30.4, 
30.3, 30.0, 28.1, 28.0, 27.9, 27.7, 27.6 (CH2). ESIMS: m/z 758.4 [M + Na]+. Anal. Calcd for 
C25H34F13N3O5S: C, 40.82; H, 4.66; N, 5.71; S, 4.36. Found: C, 40.86; H, 4.52; N, 5.54; S, 4.07. 
Commercial Enzyme Inhibition Assays. Inhibition constant (Ki) values were determined by 
spectrophotometrically measuring the residual hydrolytic activities of the glycosidases against 
the respective o- (for β-galactosidase from E. coli) or p-nitrophenyl α- or β-D-glycopyranoside 
(for other glycosidases) in the presence of the iminosugars. Each assay was performed in 
phosphate buffer or phosphate-citrate buffer (for α- or β-mannosidase and amyloglucosidase) at 
the optimal pH for the enzymes. The reactions were initiated by addition of the enzyme to a 
solution of the substrate in the absence or presence of various inhibitor concentrations. The 
mixture was incubated for 10-30 min at 37 ºC or 55 ºC (for amyloglucosidase) and the reaction 
was quenched by addition of 1 M Na2CO3. Reaction times were appropriate to obtain 10-20% 
conversion of the substrate in order to achieve linear rates. The absorbance of the resulting 
mixture was determined at 405 nm. Approximate values of Ki were determined using a fixed 
concentration of substrate (around the KM value for the different glycosidases) and various 
inhibitor concentrations. Full Ki determinations and the enzyme inhibition mode were 
determined from the slope of Lineweaver-Burk plots and double reciprocal analysis. 
Representative examples of the Lineweaver-Burk plots are shown in Figures S11-S18. 
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Critical Micellar Concentration (CMC) Determinations. CMC was determined using a 
methodology based on the environmental dependence of pyrene fluorescence.60 A pyrene stock 
solution (1 mM in THF) was diluted with Milli-Q water to give a final concentration of 0.6 µM. 
This solution was subsequently used to prepare solutions of iminosugars ranging from 1180 to 
4.3 · 10-3 µM. The samples were allowed to equilibrate for 1 h at 37 °C. Measurements were 
carried out at λem 375 nm. The ratio of the fluorescence intensities at λex 339 (I339) and 335 (I335) 
nm was used to quantify the shift of the broad excitation band. Finally, the critical aggregation 
concentrations were determined from the crossover point when representing the log[iminosugar] 
vs I339/I335 ratio (See SI, Figures S19-S22).  
NMR-Monitoring of Chaperone:βCD Complex Formation, Titration Experiments and 
Association Constant Determinations. 
1H NMR spectra of 1 mM suspensions or solutions of 
the fluorinated sp2-iminosugars 21-24 (5% DMSO-d6 in D2O) were registered at 298 K in the 
absence and in the presence of equimolecular amounts of βCD. The rise of the intensity of the 
sp2-iminosugar resonances upon addition of βCD was indicative of the solubilizing capabilities 
of βCD. On the other hand, the up-field shifts of 1H NMR βCD signals (especially H-3 and H-5 
resonances) unequivocally demontrated the formation of an inclusion complex (Figures S24-
S27). Association constants (Kas) for the complexes 21:βCD and 22:βCD were additionally 
determined in D2O at 298 K by measuring the chemical shift variations either in the 1H or 19F 
NMR spectra (500 and 376 MHz, respectively) of a solution of one of the components in the 
presence of increasing amounts of its counterpart. In a typical titration experiment, a stock 
solution of βCD (0.3-0.5 mM) in D2O was prepared. A 500 µL-aliquot of this solution was 
transferred to a NMR tube and the initial NMR spectrum was recorded. Then, a solution (2-4 
mM) of the chaperone was prepared in the stock βCD solution in order to maintain the host 
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concentration constant all throughout the titration experiment. Aliquots of the iminosugar 
solution were sequentially added to the NMR tube and the corresponding spectrum was recorded 
after each addition until 90-100% complexation had been achieved. The chemical shifts of the 
βCD signals obtained at ca. 12-15 different host-guest concentration ratios were plotted against 
the iminosugar concentration and used in an iterative least-squares fitting procedure.62,76 
Alternatively, the titration experiment was reproduced inversely, by adding to a stock solution of 
the iminosugar (ca. 0.5 mM) increasing amounts of a concentrated solution of βCD and 
monitoring the 19F NMR resonance shifts of the fluorocarbonated chain upon complexation. 
Both, the direct and inverse Ka determination procedures afforded qualitatively similar results 
(See SI, Figures S28-S32). 
Measurement of Purified Human GCase Inhibition Activities in vitro. GCase activities 
were determined as above using purified human GCase, obtained from Genzyme (Genzyme 
Japan, Tokyo, Japan) in 0.1 M citrate buffer at pH 5 or pH 7 and 4-methylumbelliferone (4-MU)-
conjugated β-D-glucopyranoside as the substrate. The reactions were terminated by adding 0.2 
mL of 0.2 M glycine sodium hydroxide buffer (pH 10.7).  The liberated 4-methylumbelliferone 
was measured in a black-well plate with a Perkin Elmer Luminescence Spectrometer (excitation 
wavelength: 340 nm; emission: 460 nm). 
Profiling of the Inhibitory Selectivity Towards Lysosomal Glycosidases by in vitro 
Enzyme Assay. For determination of lysosomal enzyme activities in cell lysates, cells were 
scraped into ice-cold H2O (106 cells mL-1) and lysed by sonication. Insoluble materials were 
removed by centrifugation at 15,000 rpm for 5 min and protein concentrations were determined 
with Protein Assay Rapid Kit (WAKO, Tokyo, Japan). 10 µL of the lysates in 0.1% Triton X-
100 in distilled water were incubated at 37 °C with 20 µL of the substrate solution in 0.1 M 
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citrate buffer, pH 4.5, in absence or presence of increasing concentrations of the chaperones or 
their complexes with βCD. The substrates were 4-methylumbelliferone (4-MU)-conjugated β-D-
glucopyranoside (for GCase), α-D-glucopyranoside (for α-glucosidase), α-D-galactopyranoside 
(for α-Galase), β-D-galactopyranoside (for β-galactosidase), N-acetyl-β-D-glucosaminide (for 
total β-hexosaminidase) and α-N-acetyl-D-galactosaminide for α-N-acetylgalactosaminidase. 
GCase activities in cell lysates were also determined in 0.1 M citrate buffer at pH 5 or pH 7, 
supplemented with sodium taurocholate (0.8% w/v). The reactions were terminated by adding 
0.2 mL of 0.2 M glycine sodium hydroxide buffer (pH 10.7).  The liberated 4-
methylumbelliferone was measured in the black-well plate with a Perkin Elmer Luminescence 
Spectrometer (excitation wavelength: 340 nm; emission: 460 nm). One unit of enzyme activity 
was defined as nmol of 4-methylumbelliferone released per hour and normalized for the amount 
of protein contained in the lysates. The fluorinated chaperones 21-24, either in free form or 
complexed with βCD, showed total selectivity towards GCase (IC50 0.1-30 µM) in this assay 
(less than 20% inhibition of any other of the assayed lysosomal glycosidases at 100 µM 
concentration). 
Cell Cultures, Chaperone Tests and Toxicity Assays. Normal and Gaucher disease patients’ 
skin fibroblasts were cultured in Dulbecco modified Eagle’s medium (WAKO) supplemented 
with 10% fetal bovine serum (Nichirei Biosci. Inc., Tokyo, Japan) at 37 ºC in 5% CO2. For 
measurement of chaperone activities, fibroblasts were plated onto 35 mm dishes at 50,000 cells 
per dish. After 24 h incubation, the medium with the indicated concentrations of compound was 
applied and cells were cultured for 96 hours. Then, the lysates in 0.1% Triton-X100/distilled 
H2O were collected from the cells and assayed for lysosomal GCase as described above. To 
measure the cytotoxic effect of the compounds, normal human fibroblasts were plated onto 35 
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mm dishes at 15,000 cells per dish and incubated overnight. Then the medium was changed with 
or without compounds. After 24 h incubation, the supernatant of the cells was collected and 
measured by the lactate dehydrogenase assay (WAKO). All the cell lines used were tested for 
mycoplasma contamination before conducting the chaperone and toxicity assays. 
Immunofluorescence Microscopy. Immunofluorescence microscopy was performed using 
standard methods as previously described.40 Cover slips were analyzed using a fluorescence 
microscope (Leica DMRE, Leica Microsystems GmbH, Wetzlar, Germany). Deconvolution 
studies and 3-dimensional projections were performed using a DeltaVision system (Applied 
Precision, Issaquah, WA) with an Olympus IX-71microscope. The deconvolved images were 
derived from optical sections taken at 30-nm intervals using a 60× PLAPON objective with a 
1.42 numerical aperture. More than 100 cells in 10 randomly obtained images were evaluated in 
each experiment to confirm reproducibility. 
Docking Experiments. The structure of wild type human GCase was modeled by homology-
based simulated annealing  using Modeller  9v777 and the X-ray diffraction models of Gcase at 
pH 4.5 and 5.5 (pdb codes: 1OGS, 3GXM and  3GXI)65,78 and  of the partially deglycosylated 
enzyme at pH 6 (pdb: 2F61).79  The RMSD value between the distinct structures were lower than 
0.4 Å. MOL2 coordinate files of the chaperones were obtained with ChemOffice (PerkinElmer) 
and submitted  to flexible docking  with the enzyme using Autodock Vina80 and monitored in 
UCSF Chimera.81 Both, the ligand and protein loops were treated as flexible. The best of the 10 
lowest score structures were selected in each computation, and then submitted to energy 
minimization and MD (20 ns MD trajectories) for further refinement. The Antechamber82 
module of Amber 1483 was used to assign the general Amber force field parameters84 and AM1-
BCC charges85 to the PC models. Simulations were performed under periodic boundary 
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conditions using orthorhombic cell geometry (the minimum distance between protein and cell 
faces was initially set at 10 Å) and particle mesh Ewald (PME) electrostatics with a Ewald 
summation cutoff of 9 Å. The structures were solvated with extended simple point charge model 
(SPC) water molecules,86 and Cl- counter-ions were added to neutralize the net charge of the full 
systems. Afterwards, solvent and counter-ions were subjected to 2500 steps of steepest descent 
minimization followed by 500 ps NPT-MD computations using isotropic molecule position 
scaling and a pressure relaxation time of 2 ps at 298 K. Then, energy minimization was carried 
out in the overall system, which was then submitted to 300 ps temperature equilibration to 298 K 
followed by a production run under the microcanonical ensemble. The SHAKE algorithm87 was 
used to constrain bonds involving hydrogen atoms. The PTRAJ module of AMBER and 
LIGPLOT88 were used for data analyses. 
Statistical Analysis. All results are expressed as mean±SD of three independent experiments, 
each conducted in triplicate. The measurements were statistically analyzed using the Student’s t 
test for comparing 2 groups. The level of significance was set at p<0.05. 
 
ASSOCIATED CONTENT 
Supporting Information 
PDB files for the computational models obtained after docking of compound 22 and compound 
11 with GCase (Figures 6 and S1), 1H NMR and 13C NMR spectra of all new compounds, 
Lineweaver-Burk plots for Ki and enzyme inhibition mode determinations, excitation spectra of 
pyrene in water containing increasing concentrations of the fluorinated chaperones 21-24 and 
plots for CMC determinations, 1H NMR spectra of the 1:1 inclusion complexes of 21-24 with 
βCD, selected 1H or 19F NMR spectra from titration experiments as well as the corresponding 
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binding isotherm plots, and toxicity data for compounds 21-24 and their complexes with β-
cyclodextrin in healthy human fibroblasts. This material is available free of charge via the 
Internet at http://pubs.acs.org. 
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